{"filings":[{"id":94715,"accession_number":"0001690585-26-000021","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dianthus Q1 net loss $40.8M; cash $1.2B; claseprubart and DNTH212 advance","event_type":"earnings","confidence":"high","bullets":["Net loss $40.8M ($0.85/share) vs $29.5M ($0.82) in Q1 2025; R&D spend $34.5M up from $27.0M.","Cash $1.2B at March 31, including $719M gross from March public offering; runway into 2030.","Claseprubart: Early GO in CAPTIVATE CIDP trial; Phase 3 gMG trial mid-2026 with top-line 2H'28.","DNTH212: Priority indications SjD, SLE, DM; Phase 1 healthy volunteer data expected 2H'26.","Orphan Drug Designation for claseprubart in MG; FDA agreed to remove ANA screening and DIL reclassification."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107303,"accession_number":"0001690585-26-000010","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA agrees to remove ANA screening, reclassify lupus risk for Dianthus' claseprubart trials","event_type":"regulatory","confidence":"high","bullets":["FDA agreed to remove anti-nuclear antibodies (ANAs) as screening criteria for all ongoing and future claseprubart trials.","Routine ANA testing during claseprubart trials will be eliminated per FDA feedback.","Hypothetical risk reclassified from systemic lupus erythematosus (SLE) to drug-induced lupus (DIL), a reversible side effect.","No cases of SLE or DIL have been observed in any claseprubart program to date.","Company posted an updated corporate presentation on its website summarizing these changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107302,"accession_number":"0001193125-26-103053","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Dianthus Therapeutics raises ~$673.5M in public offering of common stock and pre-funded warrants","event_type":"other_material","confidence":"high","bullets":["Offering of 7,313,582 shares at $81.00/share and pre-funded warrants for 402,468 shares at $80.999/share.","Underwriters exercised in full option to purchase additional 1,157,407 shares on March 11, 2026.","Net proceeds expected to be approximately $673.5 million after underwriting discounts and expenses.","Offering expected to close March 12, 2026; securities offered under shelf registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107301,"accession_number":"0001193125-26-097555","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Dianthus announces early GO decision in Phase 3 CAPTIVATE CIDP trial; reports FY2025 results","event_type":"other_material","confidence":"high","bullets":["Early GO decision: 20 confirmed responders with less than 40 participants; DSMB confirmed; no serious infections or discontinuations.","Plans to drop 600mg dose arm in Part B; enroll up to 256 patients (down from 480) to randomize 128 (down from 192).","FY2025 net loss $162.3M ($4.20/share) vs $85.0M ($2.55/share) in FY2024.","Cash $514.4M provides runway into 2028.","Phase 3 gMG trial of claseprubart to start mid-2026; top-line data expected 2H’28."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107300,"accession_number":"0001193125-26-009898","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Dianthus expects ~$514M cash at year-end 2025; CEO to present at JPM conference","event_type":"other_material","confidence":"high","bullets":["Preliminary unaudited cash, cash equivalents, and short-term investments of ~$514M as of Dec 31, 2025.","Actual results may differ materially due to completion of financial closing procedures.","CEO Marino Garcia to present at 44th Annual J.P. Morgan Healthcare Conference on Jan 12, 2026.","Presentation focuses on advancing the autoimmune-focused pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123660,"accession_number":"0001193125-25-266867","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dianthus reports Q3 net loss $36.8M; gMG Ph2 data positive, CIDP Ph3 interim accelerated to Q2'26","event_type":"earnings","confidence":"high","bullets":["Net loss of $36.8M ($0.97/share) vs $25.2M ($0.74/share) Q3'24; R&D $32.5M on higher clinical costs.","Phase 2 MaGic trial of claseprubart in gMG met endpoints with stat sig MG-ADL and QMG improvements at Week 13.","CIDP Phase 3 CAPTIVATE trial interim responder analysis accelerated to Q2'26 (from 2H'26) due to faster enrollment.","In-licensed DNTH212 (bifunctional BDCA2/BAFF-APRIL inhibitor) from Leads Biolabs; Ph1 healthy volunteer data expected 2H'26.","Adjusted cash ~$525M after $30M DNTH212 milestone payments; runway into 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":1752000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.78,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123659,"accession_number":"0001193125-25-262188","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Dianthus Therapeutics posts updated corporate presentation; no specific material changes disclosed","event_type":"other","confidence":"low","bullets":["Updated corporate presentation posted on company's investor relations website on November 3, 2025.","Presentation filed as Exhibit 99.1 to the 8-K; detailed content not available in the excerpt provided.","No financial results, pipeline updates, or guidance changes are included in the filing text.","Routine update; no material new operational or strategic information identified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123658,"accession_number":"0001193125-25-240858","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["1.01","2.02","8.01","9.01"],"status":"ready","headline":"Dianthus licenses DNTH212 from Leads Biolabs; $30M upfront, $962M potential milestones","event_type":"other_material","confidence":"high","bullets":["Up to $38M in upfront and near-term payments ($30M cash plus $8M milestone at Phase 1 start).","Additional up to $962M in development, regulatory, and sales-based milestones across five indications.","Tiered royalties from mid-single digits to low double-digit on ex-Greater China net sales.","Preliminary cash $555M as of Sep 30, 2025; pro forma $525M after $30M payment to Leads."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140345,"accession_number":"0001193125-25-200715","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Dianthus raises ~$270M in public offering of common stock and pre-funded warrants","event_type":"other_material","confidence":"high","bullets":["Issued 6,487,879 common shares at $33.00/share and 1,112,121 pre-funded warrants at $32.999/share.","Underwriters exercised in full option for additional 1,140,000 shares.","Net proceeds expected to be approximately $270 million after discounts and expenses.","Offering priced Sept 9, 2025; closing expected Sept 11, 2025.","Pre-funded warrants exercisable at any time; beneficial ownership cap of 4.99%-19.99%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140344,"accession_number":"0001193125-25-197751","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Dianthus reports positive Phase 2 MaGic trial for claseprubart in gMG; both doses meet endpoints","event_type":"other_material","confidence":"high","bullets":["Claseprubart 300mg Q2W: MG-ADL mean change -4.6 (placebo-adjusted -1.8, p=0.0113); QMG -4.4 (adj. -2.4, p=0.0144) at Week 13.","Claseprubart 600mg Q2W: MG-ADL mean change -5.4 (adj. -2.6, p=0.0006); QMG -4.5 (adj. -2.5, p=0.0111).","Rapid onset: both doses showed stat. significant MG-ADL and QMG improvement as early as Week 1.","Favorable safety: no related serious infections, SAEs, or discontinuations; no Boxed Warning or REMS anticipated for planned autoinjector.","Phase 3 gMG trial evaluating 300mg Q2W and Q4W vs placebo planned to start in 2026; CIDP and MMN data expected 2H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140343,"accession_number":"0000950170-25-105002","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dianthus Q2 net loss $31.6M ($0.88/sh); cash $309.1M; gMG Ph2 data due Sept","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and investments $309.1M as of June 30, 2025; runway into 2H 2027.","Net loss $31.6M ($0.88 basic/diluted EPS) vs $17.6M ($0.51) in Q2 2024.","R&D expenses $26.3M (incl. $2.5M stock-based) vs $18.1M; increase driven by Phase 2/3 costs.","Top-line Phase 2 MaGic trial results for claseprubart in gMG anticipated September 2025.","Phase 3 CAPTIVATE CIDP trial on track; interim responder analysis expected 2H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":1356000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157989,"accession_number":"0000950170-25-076304","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Dianthus director Moulder resigns; Read appointed as Class III director","event_type":"leadership","confidence":"high","bullets":["Leon O. Moulder, Jr. resigned from Board effective May 22, 2025, with no disagreement.","Board appointed Simon Read, Ph.D. as Class III director and to S&T and N&CG Committees.","Dr. Read receives initial option for 25,000 shares vesting over 3 years; cash compensation of $40k/yr plus $5k per committee.","Annual meeting elected Garcia and Soteropoulos as Class I directors; advisory vote approved exec compensation; Deloitte ratified as auditor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}